December 25, 2024 12:51 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Former home secy Ajay Kumar Bhalla appointed Manipur Guv amid ethnic violence resurgence | Five soldiers killed, several injured as Army truck falls into Poonch gorge | Allu Arjun quizzed by police in Pushpa 2 stampede case | Wanted Indian drug smuggler killed in the US | Congress leader files complaint against Allu Arjun for 'insulting police' in Pushpa 2: The Rule | Ahead of Jaishankar's US visit, foreign secretary Vikram Misri meets top US diplomats | India refrains from commenting on extradition request for ousted Bengladeshi PM Sheikh Hasina | I don't blame Allu Arjun, ready to withdraw case: Pushpa 2 stampede victim's husband | Indian New Wave Cinema Architect Shyam Benegal dies at age 90 | Cylinder blast at a temple in Karnataka's Hubbali injures nine people

Sun Pharma Q4FY24 PAT grows 34% to Rs 2,655 cr; Rs 5 per share dividend declared

| @indiablooms | May 23, 2024, at 03:40 am

Mumbai: Leading pharmaceutical company Sun Pharmaceutical Industries Ltd announced a consolidated net profit of Rs 2,654.5 crore for the March quarter, a 34 percent increase from the same period last year, media reported.

The consolidated revenue was reported at Rs 11,982.9 crore, a 9 percent rise compared to Rs 10,930.6 crore a year earlier, reported Moneycontrol.

The company's board also declared a final dividend of Rs 5 per equity share for the financial year 2023-24.

Operating EBITDA grew by 8.3 percent to Rs 3,034 crore, up from Rs 2,802 crore in the previous fiscal year.

The EBITDA margin was 25.3 percent, slightly down from 25.6 percent in the same period last year.

For the full year FY24, external API sales were Rs 1,918.7 crore, a decrease of 2.7 percent from the previous year, said the report.

US formulation sales for the full year FY24 were $1,854 million, an increase of 10.1 percent compared to the same period last year.

In Q4 FY24, US formulation sales were $476 million, a growth of 10.9 percent over Q4 of the previous year, making up 33.5 percent of total consolidated sales for the quarter, stated the report.

Global specialty sales reached $271 million, up 11.1 percent year-on-year. Formulation sales in Emerging Markets for the full year FY24 were $1,041 million, up 5.9 percent from the previous year.

Emerging Markets sales for Q4 FY24 were $245 million, growing 10.8 percent from Q4 of the previous year and accounting for 17.2 percent of total consolidated sales for the quarter.

R&D investments for the quarter were Rs 900 crore, compared to Rs 665.7 crore in Q4 FY23.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.